問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2025-10-18

張旭良
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

8Cases

2025-10-01 - 2028-12-31

Active
A phase 2b, randomized, double-blind, placebo-controlled, parallel, multiple-dose trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of AZD0292 in patients aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa grafts.
  • Condition/Disease

    In NCFBE and chronic PsA transfer subjects, the effect of AZD0292 IV every 4 weeks (Q4W) compared with placebo on the incidence of moderate to severe acute lung exacerbations was evaluated.

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2025-06-01 - 2028-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-06-01 - 2028-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2025-03-01 - 2028-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-11-25 - 2027-04-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2026-03-01 - 2031-11-10

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-12-31 - 2029-11-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-10-01 - 2027-10-01

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites